<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02313207</url>
  </required_header>
  <id_info>
    <org_study_id>CLE-IBS-2</org_study_id>
    <nct_id>NCT02313207</nct_id>
  </id_info>
  <brief_title>Confocal Laser Endomicroscopy in IBS Patients</brief_title>
  <official_title>Confocal Endomicroscopy for the Detection of Food Intolerances in Patients With IBS.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess dynamic effects of two major antigens on the duodenal mucosa by&#xD;
      confocal laser endomicroscopy (CLE). Patients will be blinded to the antigens used (wheat,&#xD;
      yeast). Following CLE it is planned to have a cross over exclusion diet with/without the&#xD;
      antigens including a washout phase. Furthermore, patients will undergo a 2 week FODMAP diet&#xD;
      to be able to compare results found of both diets and allow to understand whether our&#xD;
      findings of food intolerance will be better and more precise than a common FODMAP diet.&#xD;
&#xD;
      Post CLE food challenge patients biopsies will be taken for histology. They will then be&#xD;
      randomized into two groups and blinded to the diet they undergo. They will be provided with a&#xD;
      supply of custom-made bread they will have for 2 weeks (custom made by a bakery in Kiel). For&#xD;
      one study arm bread will contain either wheat and yeast, for the other arm the bread will not&#xD;
      contain these ingredients. The taste of the &quot;normal&quot; bread will be denaturised. Crossover&#xD;
      will take place after a two-week washout phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of mucosal reaction on allergen exposure</measure>
    <time_frame>up to 5 sec</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>IBS</condition>
  <condition>Food Intolerance</condition>
  <arm_group>
    <arm_group_label>FODMAP diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FODMAP diet for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Specific bread diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Specific bread diet eliminating wheat and yeast for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>FODMAP</intervention_name>
    <description>patients will undergo a specific FODMAP diet for a period of 2 weeks.</description>
    <arm_group_label>FODMAP diet</arm_group_label>
    <arm_group_label>Specific bread diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        IBS according to the Rome III criteria moderate/severe refractory daily symptoms &gt;1year&#xD;
        (FGID-C1) sub classified as IBS-D, constipation predominant (IBS-C) or mixed type (IBS-M)&#xD;
        no past infection to trigger symptom no structural/ biochemical cause of their symptoms&#xD;
        identified negative gastroscopy, colonoscopy including histology Worsening symptoms after&#xD;
        meals various exclusion diets - ineffective females not menstruating during CLE no known&#xD;
        allergy to methylene blue or fluorescein Age &gt;18 years Negative routine testing for food&#xD;
        intolerance (or known lactose/fructose intolerance) Positive informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        no consent known reason for the abdominal pain and bloating other than lactose/fructose&#xD;
        intolerance M. Whipple Known infectious gastrointestinal disease Stricture in the upper&#xD;
        gastrointestinal tract Age &lt;18years Impaired renal function (Creatinine &gt;1.2 mg/dL)&#xD;
        Pregnancy or breast-feeding Inability to obtain informed consent Active GI Bleeding Known&#xD;
        allergy to Methylene blue or Fluorescein Participation in other clinical trials within the&#xD;
        last 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annette Fritscher-Ravens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Schleswig-Holstein</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Ellrichmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Schleswig-Holstein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annette Fritscher-Ravens, MD, PhD</last_name>
    <phone>00494315972075</phone>
    <email>fri.rav@btopenworld.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Ellrichmann, MD</last_name>
    <phone>00494315972075</phone>
    <email>mark.ellrichmann@uksh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Schleswig Holstein, Campus Kiel, Unit Experimental Endoscopy</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Fritscher-Ravens, Prof. Dr.</last_name>
      <phone>00494315972311</phone>
      <email>fri.rav@btopenworld.com</email>
    </contact>
    <contact_backup>
      <last_name>Mark Ellrichmann, MD</last_name>
      <phone>00494315971358</phone>
      <email>mark.ellrichmann@uk-sh.de</email>
    </contact_backup>
    <investigator>
      <last_name>Annette Fritscher-Ravens, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Ellrichmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Mark Ellrichmann</investigator_full_name>
    <investigator_title>Senior Consultant, Unit of Experimental Endoscopy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Food Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

